Last reviewed · How we verify
Interferon Beta-1A Prefilled Syringe
Interferon Beta-1A binds to type I interferon receptors on cell surfaces to activate antiviral and immunomodulatory pathways.
Interferon Beta-1A binds to type I interferon receptors on cell surfaces to activate antiviral and immunomodulatory pathways. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.
At a glance
| Generic name | Interferon Beta-1A Prefilled Syringe |
|---|---|
| Also known as | CinnoVex® |
| Sponsor | Cinnagen |
| Drug class | Interferon |
| Target | Type I interferon receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon Beta-1A is a recombinant cytokine that engages type I interferon receptors (IFNAR1 and IFNAR2), triggering JAK-STAT signaling cascades that enhance natural killer cell activity, increase antigen presentation, and reduce pro-inflammatory cytokine production. This results in immunomodulation and reduced disease activity in autoimmune conditions, particularly multiple sclerosis.
Approved indications
- Relapsing-remitting multiple sclerosis
- Secondary progressive multiple sclerosis
Common side effects
- Injection site reactions
- Flu-like symptoms (fever, chills, myalgia)
- Headache
- Fatigue
- Depression
- Elevated liver enzymes
- Leukopenia
Key clinical trials
- Trial of Treatments for COVID-19 in Hospitalized Adults (PHASE3)
- Early Interferon-beta Treatment for West-Nile Virus Infection (PHASE2)
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis (PHASE3)
- Adaptive COVID-19 Treatment Trial 3 (ACTT-3) (PHASE3)
- Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) (PHASE1)
- Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects (PHASE3)
- The Multicenter, Open-label, Single-use Autoinjector Convenience Study (PHASE3)
- Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |